Retatrutide

Retatrutide is a triple receptor agonist at GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, studied for synergistic effects on energy substrate utilisation, incretin signalling, and adipose tissue lipolysis in preclinical models. As one of the most actively investigated next-generation incretin-class compounds, it is of significant interest in metabolic signalling pathway research, receptor co-activation studies, and energy homeostasis modelling — pharmacist-formulated and independently third-party tested. COA available.